Preliminary data from 103 patients in the expansion portion of a Phase 1b clinical trial demonstrated the drug was well tolerated and anti-tumor activity was noted
- Unique opportunity to leverage CELsignia platform to advance development of a first-in-class targeted therapy
- Management to host conference call/webcast today, April 8, 2021, at 5:00 p.m. ET
The Celcuity management team will host a webcast/conference call today, April 8, 2021, at 5:00 p.m. ET to discuss the gedatolisib license agreement. To participate in the call, dial 1-877-407-8035. A live webcast presentation can also be accessed using this weblink at: https://www.webcaster4.com/Webcast/Page/2678/40570 or via Celcuity’s website at https://celcuity.com/home/investors/events-webcasts/. A replay of the webcast will be available on the Celcuity website for a limited time following the event.
https://finance.yahoo.com/news/celcuity-announces-worldwide-licensing-agreement-200200767.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.